Stem cell transplantation with chemoradiotherapy myeloablation and interleukin-2.

K. R. Meehan, U. N. Verma, C. Rajogopal, R. Cahill, S. Frankel, A. Mazumder

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Interleukin 2 (IL-2) stimulates the proliferation of T-cells both in vitro and in vivo. When murine or human peripheral blood (PB) or bone marrow (BM) mononuclear cells are incubated with IL-2 in vitro for 24 hours, cytotoxic T-cells are generated. If these activated cells are infused into mice, the enhanced cytotoxicity continues if low dose IL-2 is administered. This combination of administering activated cells with the subsequent low dose IL-2 infusion results in enhanced tumor cell destruction and improved survival rates in mice with acute myeloid leukemia. The encouraging results of these laboratory experiments prompted the initiation of phase I clinical trials in patients with refractory/relapsed hematologic malignancies and patients with breast cancer (Stages II-IV). Results from these trials demonstrate that stem cell transplantation with IL-2 activated stem cells (either PB or BM) with or without parenteral administration of IL-2 results in hematopoietic reconstitution with mild-to-moderate toxicities. This regimen also generates cutaneous and visceral autologous graft versus host disease (AuGVHD). The majority of our patients with relapsed/refractory hematologic malignancies or breast cancer developed either clinical and/or histological evidence of AuGVHD. Further studies are being conducted to determine if patients who develop AuGVHD experience improved disease-free survival from a possible autologous graft versus tumor (GVT) effect. Current laboratory evaluations include the elucidation of the pathogenesis of AuGVHD and molecular evaluation of the purging efficacy of IL-2.

Original languageEnglish (US)
Pages (from-to)28-32
Number of pages5
JournalThe Journal of infusional chemotherapy
Volume6
Issue number1
StatePublished - Dec 1996

Fingerprint

Stem Cell Transplantation
Chemoradiotherapy
Interleukin-2
Graft vs Host Disease
Hematologic Neoplasms
Breast Neoplasms
T-Lymphocytes
Clinical Trials, Phase I
Acute Myeloid Leukemia
Bone Marrow Cells
Disease-Free Survival
Neoplasms
Survival Rate
Bone Marrow
Transplants
Skin

ASJC Scopus subject areas

  • Microbiology

Cite this

Meehan, K. R., Verma, U. N., Rajogopal, C., Cahill, R., Frankel, S., & Mazumder, A. (1996). Stem cell transplantation with chemoradiotherapy myeloablation and interleukin-2. The Journal of infusional chemotherapy, 6(1), 28-32.

Stem cell transplantation with chemoradiotherapy myeloablation and interleukin-2. / Meehan, K. R.; Verma, U. N.; Rajogopal, C.; Cahill, R.; Frankel, S.; Mazumder, A.

In: The Journal of infusional chemotherapy, Vol. 6, No. 1, 12.1996, p. 28-32.

Research output: Contribution to journalArticle

Meehan, KR, Verma, UN, Rajogopal, C, Cahill, R, Frankel, S & Mazumder, A 1996, 'Stem cell transplantation with chemoradiotherapy myeloablation and interleukin-2.', The Journal of infusional chemotherapy, vol. 6, no. 1, pp. 28-32.
Meehan, K. R. ; Verma, U. N. ; Rajogopal, C. ; Cahill, R. ; Frankel, S. ; Mazumder, A. / Stem cell transplantation with chemoradiotherapy myeloablation and interleukin-2. In: The Journal of infusional chemotherapy. 1996 ; Vol. 6, No. 1. pp. 28-32.
@article{0255f64386e7491d8a86cac311e922a8,
title = "Stem cell transplantation with chemoradiotherapy myeloablation and interleukin-2.",
abstract = "Interleukin 2 (IL-2) stimulates the proliferation of T-cells both in vitro and in vivo. When murine or human peripheral blood (PB) or bone marrow (BM) mononuclear cells are incubated with IL-2 in vitro for 24 hours, cytotoxic T-cells are generated. If these activated cells are infused into mice, the enhanced cytotoxicity continues if low dose IL-2 is administered. This combination of administering activated cells with the subsequent low dose IL-2 infusion results in enhanced tumor cell destruction and improved survival rates in mice with acute myeloid leukemia. The encouraging results of these laboratory experiments prompted the initiation of phase I clinical trials in patients with refractory/relapsed hematologic malignancies and patients with breast cancer (Stages II-IV). Results from these trials demonstrate that stem cell transplantation with IL-2 activated stem cells (either PB or BM) with or without parenteral administration of IL-2 results in hematopoietic reconstitution with mild-to-moderate toxicities. This regimen also generates cutaneous and visceral autologous graft versus host disease (AuGVHD). The majority of our patients with relapsed/refractory hematologic malignancies or breast cancer developed either clinical and/or histological evidence of AuGVHD. Further studies are being conducted to determine if patients who develop AuGVHD experience improved disease-free survival from a possible autologous graft versus tumor (GVT) effect. Current laboratory evaluations include the elucidation of the pathogenesis of AuGVHD and molecular evaluation of the purging efficacy of IL-2.",
author = "Meehan, {K. R.} and Verma, {U. N.} and C. Rajogopal and R. Cahill and S. Frankel and A. Mazumder",
year = "1996",
month = "12",
language = "English (US)",
volume = "6",
pages = "28--32",
journal = "Journal of Spirochetal and Tick-borne Diseases",
issn = "1060-0051",
publisher = "Slack Incorporated",
number = "1",

}

TY - JOUR

T1 - Stem cell transplantation with chemoradiotherapy myeloablation and interleukin-2.

AU - Meehan, K. R.

AU - Verma, U. N.

AU - Rajogopal, C.

AU - Cahill, R.

AU - Frankel, S.

AU - Mazumder, A.

PY - 1996/12

Y1 - 1996/12

N2 - Interleukin 2 (IL-2) stimulates the proliferation of T-cells both in vitro and in vivo. When murine or human peripheral blood (PB) or bone marrow (BM) mononuclear cells are incubated with IL-2 in vitro for 24 hours, cytotoxic T-cells are generated. If these activated cells are infused into mice, the enhanced cytotoxicity continues if low dose IL-2 is administered. This combination of administering activated cells with the subsequent low dose IL-2 infusion results in enhanced tumor cell destruction and improved survival rates in mice with acute myeloid leukemia. The encouraging results of these laboratory experiments prompted the initiation of phase I clinical trials in patients with refractory/relapsed hematologic malignancies and patients with breast cancer (Stages II-IV). Results from these trials demonstrate that stem cell transplantation with IL-2 activated stem cells (either PB or BM) with or without parenteral administration of IL-2 results in hematopoietic reconstitution with mild-to-moderate toxicities. This regimen also generates cutaneous and visceral autologous graft versus host disease (AuGVHD). The majority of our patients with relapsed/refractory hematologic malignancies or breast cancer developed either clinical and/or histological evidence of AuGVHD. Further studies are being conducted to determine if patients who develop AuGVHD experience improved disease-free survival from a possible autologous graft versus tumor (GVT) effect. Current laboratory evaluations include the elucidation of the pathogenesis of AuGVHD and molecular evaluation of the purging efficacy of IL-2.

AB - Interleukin 2 (IL-2) stimulates the proliferation of T-cells both in vitro and in vivo. When murine or human peripheral blood (PB) or bone marrow (BM) mononuclear cells are incubated with IL-2 in vitro for 24 hours, cytotoxic T-cells are generated. If these activated cells are infused into mice, the enhanced cytotoxicity continues if low dose IL-2 is administered. This combination of administering activated cells with the subsequent low dose IL-2 infusion results in enhanced tumor cell destruction and improved survival rates in mice with acute myeloid leukemia. The encouraging results of these laboratory experiments prompted the initiation of phase I clinical trials in patients with refractory/relapsed hematologic malignancies and patients with breast cancer (Stages II-IV). Results from these trials demonstrate that stem cell transplantation with IL-2 activated stem cells (either PB or BM) with or without parenteral administration of IL-2 results in hematopoietic reconstitution with mild-to-moderate toxicities. This regimen also generates cutaneous and visceral autologous graft versus host disease (AuGVHD). The majority of our patients with relapsed/refractory hematologic malignancies or breast cancer developed either clinical and/or histological evidence of AuGVHD. Further studies are being conducted to determine if patients who develop AuGVHD experience improved disease-free survival from a possible autologous graft versus tumor (GVT) effect. Current laboratory evaluations include the elucidation of the pathogenesis of AuGVHD and molecular evaluation of the purging efficacy of IL-2.

UR - http://www.scopus.com/inward/record.url?scp=0030527380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030527380&partnerID=8YFLogxK

M3 - Article

C2 - 8748004

AN - SCOPUS:0030527380

VL - 6

SP - 28

EP - 32

JO - Journal of Spirochetal and Tick-borne Diseases

JF - Journal of Spirochetal and Tick-borne Diseases

SN - 1060-0051

IS - 1

ER -